2 completed, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
Follow Essential Thrombocythaemia: new trials by email Literature Review of Essential Thrombocythaemia trials Research Report on Essential Thrombocythaemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients Ropeginterferon alfa-2b (BESREMi®) - Essential Thrombocythaemia | Phase 3 | Active not recruiting | AOP Orphan Pharmaceuticals AG | 117 | 2023-12-04 | 2024-12-19 |
| Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Anagrelide retard, Placebo - Essential Thrombocythaemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 146 | 2010-12-01 | 2016-05-26 |
| Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia Anagrelide, Hydroxyurea - Essential Thrombocythaemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 2002-09-01 | 2010-10-06 |
Thrombocythemia, Essential (3) · Thrombocytosis (1)
Blood Coagulation Disorders (3) · Blood Platelet Disorders (3) · Bone Marrow Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hemorrhagic Disorders (3) · Myeloproliferative Disorders (3) · Thrombocytosis (2)
Hydroxyurea (1) · anagrelide (1)
AOP Orphan Pharmaceuticals AG (3)
Austria (3) · Poland (3) · Czechia (2) · France (2) · Germany (2) · Hungary (2) · Italy (2) · Lithuania (2) · Romania (2) · Bulgaria (1) · Croatia (1) · Greece (1) · Russia (1) · Singapore (1) · Slovakia (1)